Enanta Pharmaceuticals (ENTA) Projected to Post Quarterly Earnings on Monday

Enanta Pharmaceuticals (NASDAQ:ENTA) is anticipated to issue its Q1 2026 results before the market opens on Monday, February 9th. Analysts expect Enanta Pharmaceuticals to post earnings of ($0.54) per share and revenue of $16.14 million for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, February 9, 2026 at 12:00 AM ET.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.26. The business had revenue of $15.13 million during the quarter, compared to the consensus estimate of $15.60 million. Enanta Pharmaceuticals had a negative return on equity of 93.76% and a negative net margin of 125.36%. On average, analysts expect Enanta Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Enanta Pharmaceuticals Trading Up 4.2%

Shares of NASDAQ ENTA opened at $13.51 on Friday. The stock has a market cap of $392.06 million, a price-to-earnings ratio of -3.53 and a beta of 0.98. Enanta Pharmaceuticals has a 52 week low of $4.09 and a 52 week high of $17.15. The company’s 50-day moving average price is $14.11 and its 200 day moving average price is $11.27.

Wall Street Analyst Weigh In

ENTA has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Enanta Pharmaceuticals in a report on Friday, January 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, January 21st. Finally, JPMorgan Chase & Co. started coverage on shares of Enanta Pharmaceuticals in a research report on Friday, November 14th. They issued an “overweight” rating and a $17.00 target price for the company. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Enanta Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.33.

Insider Activity

In related news, insider Yat Sun Or sold 2,390 shares of Enanta Pharmaceuticals stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $34,009.70. Following the transaction, the insider owned 371,392 shares of the company’s stock, valued at approximately $5,284,908.16. This trade represents a 0.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jay R. Luly sold 4,743 shares of the company’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $67,492.89. Following the sale, the chief executive officer directly owned 858,026 shares of the company’s stock, valued at $12,209,709.98. This represents a 0.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 11,961 shares of company stock worth $170,149. Corporate insiders own 11.48% of the company’s stock.

Institutional Trading of Enanta Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Public Employees Retirement System of Ohio grew its holdings in shares of Enanta Pharmaceuticals by 8.3% during the third quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 1,100 shares in the last quarter. Ameriprise Financial Inc. boosted its position in Enanta Pharmaceuticals by 8.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock worth $216,000 after acquiring an additional 1,383 shares during the period. Russell Investments Group Ltd. grew its stake in Enanta Pharmaceuticals by 13.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company’s stock valued at $197,000 after acquiring an additional 1,940 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Enanta Pharmaceuticals by 4.3% in the 2nd quarter. Invesco Ltd. now owns 62,884 shares of the biotechnology company’s stock valued at $475,000 after purchasing an additional 2,607 shares during the period. Finally, Marshall Wace LLP increased its holdings in shares of Enanta Pharmaceuticals by 0.8% in the 2nd quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock valued at $6,482,000 after purchasing an additional 6,522 shares during the period. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.